Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesInfectious Diseaseblue cross blue shield - louisiana Lyme testing Co…
    Ask Trek AI about this page
    Modifiedblue cross blue shield - louisianaPolicy AHS - G2143 - Lyme Disease Testing

    Lyme Disease Testing

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy AHS - G2143 - Lyme Disease Testing alerts

    Get alerted when Policy AHS - G2143 - Lyme Disease Testing changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage criteria for laboratory testing to diagnose Lyme disease, specifying when serologic, molecular, and other tests meet or do not meet coverage for Blue Cross Blue Shield of Louisiana members.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyLyme Disease Testing
    Policy CodePolicy AHS - G2143 - Lyme Disease Testing
    Change TypeReorganization + material criteria additions
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateSep 15, 2026
    Key ActionWhen symptoms persist after a negative serologic test, repeat serologic testing meets coverage if performed no sooner than 4 weeks after the prior test.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Combined the contents of CC1 (symptomatic for Lyme disease) into CC2 (extreme conditions potentially caused by undiagnosed Lyme), resulting in new subcriteria and reorganization of coverage criteria.

    New CC2: When symptoms persist for individuals who tested negative by serologic testing, repeat serologic testing (no sooner than four weeks after previous test) MEETS COVERAGE CRITERIA.

    Removed reference to endemic regions in CC3.a and removed screening of asymptomatic individuals living in endemic areas.

    Removed former subcriteria 3.c (testing for nonspecific symptoms); nonspecific symptom guidance is now defined in CC1 and Note 1.

    Off-cycle coding modifications added CPT codes 0580U, 0615U and initially added 0316U previously.

    two-tierPreferred algorithm
    no testing for EMNo testing for EM
    lowPCR sensitivity
    89,000CDC cases (2023)
    09/15/2026Latest revision

    Coverage Criteria for Lyme Disease Testing

    inv-01: Serologic testing - Covered indications

    Covered when ANY of the following are met using a two-tier testing strategy (sensitive EIA/IFA followed by western immunoblot or an FDA‑cleared second EIA):

    Covered Indications: a) Early signs/symptoms of untreated Lyme disease (see Note 1) with known tick exposure or known environmental exposure (e.g., outdoor activities, contact with wildlife).; b) Later signs/symptoms of untreated Lyme disease (see Note 1) who may or may not have a known tick exposure.; c) Acute myocarditis or pericarditis of unknown cause.; d) Meningitis, encephalitis, or myelitis.; e) Painful radiculoneuritis.; f) Mononeuropathy multiplex including confluent mononeuropathy multiplex.; g) Acute cranial neuropathy.

    Two-tier serologic testing (first-tier EIA/IFA with reflex to immunoblot or FDA-cleared second-tier EIA) is required as the diagnostic strategy.

    inv-02: Repeat serologic testing

    Covered when the following condition is met:

    Repeat serology: Repeat serologic testing meets coverage criteria when symptoms persist after a negative serologic test and the repeat test is performed no sooner than four weeks after the previous test.>= 4 weeks

    Document persistent symptoms and timing of prior test; follow NICE guidance for repeat testing 4–6 weeks after initial negative when clinical suspicion remains.

    inv-03: Coverage criteria and appropriate use

    Testing is appropriate when clinical presentation and epidemiologic exposure support suspected Lyme disease; follow guideline-recommended sequencing and specimen timing.

    Serologic testing (two-tier) indicated: Patient has a compatible clinical syndrome (examples: erythema migrans when atypical or other skin lesions, neurologic syndromes such as meningitis or painful radiculoneuritis, Lyme arthritis, or acute myocarditis/pericarditis) AND testing follows a first-tier EIA or IFA with reflex to an immunoblot or an FDA-cleared second-tier EIA when the first-tier result is positive or equivocal.

    If first-tier is negative, no further testing of that specimen is recommended unless clinical course warrants repeat testing per interval guidance.

    Molecular testing utility: Molecular testing (e.g., PCR/WB‑RTPCR) may be used adjunctively in selected clinical scenarios (for example, synovial fluid PCR for suspected Lyme arthritis) but sensitivity varies by sample type and routine PCR of blood or CSF is not routinely recommended; interpret molecular results with clinical correlation.

    Guidelines recommend serum antibody testing over PCR for most presentations; PCR of synovial fluid may be informative for Lyme arthritis.

    When NOT to test: Asymptomatic patients after a tick bite; routine screening without clinical or epidemiologic support; and testing patients with nonspecific neurologic, psychiatric, or chronic disorders (e.g., ALS, MS, Parkinson's, dementia/cognitive decline, new-onset seizures, psychiatric illness) in the absence of other signs/symptoms of Lyme disease.

    inv-04: Reorganized coverage criteria (summary)

    Coverage criteria were reorganized; highlights from the revision history relevant to coverage:

    CC1 (reorganized): Includes individuals with early signs and symptoms of untreated Lyme disease who have known tick or environmental exposure, and individuals with later signs and symptoms who may or may not have known tick exposure. Individuals presenting with erythema migrans (EM) should be clinically diagnosed and treated without laboratory testing (see Note 1).

    Note 1 defines early and late signs/symptoms and clarifies EM management.

    CC2 (new): Persistent symptoms after a negative serologic test: repeat serologic testing MEETS COVERAGE CRITERIA when performed no sooner than 4 weeks after the prior test.repeat >= 4 weeks

    This is a new, material change clarifying timing and coverage stance for repeat testing.

    CC3: Former references to endemic regions were removed and replaced by guidance referencing Note 1 for applicable signs/symptoms; asymptomatic screening was removed from acceptable indications.

    Serologic testing DOES NOT MEET COVERAGE CRITERIA in specified situations. Examples include testing when an individual has an erythema migrans (EM) rash (clinical diagnosis should be made and treated without laboratory testing), screening of asymptomatic individuals, and testing performed solely for certain neurologic or psychiatric diagnoses without other supporting signs or symptoms of Lyme disease. These exclusions are explicit in the policy and reflect the updated coverage organization.

    Other scenarios explicitly listed as not meeting coverage criteria include repeat serologic testing in individuals who have previously tested positive, testing of an individual tick, and all other Borrelia testing not described in the policy's covered indications.

    The policy identifies several commercially available tests as invalid or not appropriate for diagnosis of Lyme disease, citing insufficient validation or excessive nonspecificity. Examples called out include urine antigen tests for Borrelia burgdorferi, the CD57 assay, novel culture techniques, and antibody panels that differ from standardized two‑tier testing.

    The document notes these tests are not FDA cleared, have produced false-positive or nonspecific results in independent evaluations, and therefore do not meet coverage criteria as appropriate diagnostic tests.

    The revision history clarifies that asymptomatic screening is not supported and explicitly removed prior language allowing screening of asymptomatic individuals in endemic areas. In the reorganized criteria, language was standardized by replacing the term 'patients' with 'individuals' for consistency across coverage statements.

    Note 1 was added and referenced to define signs and symptoms of early and late untreated Lyme disease; the policy reiterates that individuals presenting with EM should be clinically diagnosed and treated without laboratory testing.

    The policy states that detection of Borrelia burgdorferi by nucleic acid identification techniques (direct probe or amplified probe, e.g., PCR) DOES NOT MEET COVERAGE CRITERIA for routine diagnostic use in the contexts described.

    Guidance referenced in the policy (for example, AAP/CDC statements) further emphasize that molecular testing has limited, specific applications (such as synovial fluid PCR for Lyme arthritis) and is not a broadly supported replacement for guideline-recommended two‑tier serology.

    Serologic testing of asymptomatic individuals following a tick bite and routine testing for Lyme disease in the absence of supportive clinical or epidemiologic evidence is not recommended and does not meet coverage criteria. The CDC and other guidelines recommend against testing asymptomatic patients after an Ixodes tick bite.

    The policy requires clinical and epidemiologic indications (signs/symptoms per Note 1 and relevant exposure) to support serologic testing; routine or reflex serologic screening without such support risks denial.

    Testing for nonspecific symptoms was removed from the coverage criteria during the recent reorganization. The policy specifically eliminated the former subcriteria that allowed testing for nonspecific neurologic, psychiatric, or chronic conditions without other supporting evidence.

    As a result, serologic testing for nonspecific complaints alone is not supported unless the presentation meets the newly defined symptomatic criteria in CC1 and Note 1.

    Applicable Procedure and Proprietary Codes

    Applicable CPT/HCPCS/Proprietary Testsmixed
    86617Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot).
    86618Antibody; Borrelia burgdorferi (Lyme disease) Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, direct.
    87475Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, direct probe technique.
    87476Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique.
    0041UProprietary test: Lyme ImmunoBlot IgM; Lab/Manufacturer: IGeneX Inc.
    0042UProprietary test: Lyme ImmunoBlot IgG; Lab/Manufacturer: IGeneX Inc.
    0316UProprietary test: Lyme Borrelia Nanotrap® Urine Antigen Test; Lab/Manufacturer: Galaxy Diagnostics Inc.
    Applicable CPT/HCPCS Procedure Codesmixed
    86617Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot).
    86618Antibody; Borrelia burgdorferi (Lyme disease) Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, direct.
    87475Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, direct probe technique.
    87476Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique.
    0041UProprietary test: Lyme ImmunoBlot IgM Lab/Manufacturer: IGeneX Inc.
    0042UProprietary test: Lyme ImmunoBlots IgG Lab/Manufacturer: IGeneX Inc.
    0316UProprietary test: Lyme Borrelia Nanotrap® Urine Antigen Test. Lab/Manufacturer: Galaxy Diagnostics Inc.
    0580UCPT Proprietary code added off-cycle (documented in revision history).
    0615UCPT Proprietary code added off-cycle (documented in revision history).
    Repeat serologic testing interval — No sooner than 4 weeks after previous test
    Minimum intervalRepeat serologic testing must be performed no sooner than 4 weeks after the previous serologic test.
    Coverage conditionRepeat testing meets coverage criteria when symptoms persist after a prior negative serologic test.
    Documentation requiredWhen ordering repeat serology, document persistent symptoms and the date of the prior test to confirm the minimum interval has elapsed.

    Provider Requirements, Documentation, and Denial Risks

    Prior Authorization

    Prior authorization: document endemic travel and covered clinical indication

    Coverage requires documentation that testing is being ordered for an individual with history of travel to a region endemic for Lyme and for a specific clinical indication consistent with the policy's covered presentations (e.g., early or later signs/symptoms, acute myocarditis/pericarditis, meningitis/encephalitis/myelitis, radiculoneuritis, mononeuropathy multiplex, acute cranial neuropathy).

    • Documentation must show travel to a Lyme-endemic region when applicable.
    • Record the specific clinical indication from the policy's covered list.
    Prior Authorization

    Prior authorization for listed procedure codes: no explicit PA stated

    The policy does not state explicit prior authorization requirements for the listed CPT/HCPCS and proprietary codes; providers should follow standard payer submission rules and include the clinical documentation that supports medical necessity when submitting claims.

    • No CPT-specific prior authorization statement appears in the policy excerpt.

    Background and Evidence Summary

    Lyme disease is a tick‑borne multisystem infection in North America most commonly caused by Borrelia burgdorferi. Early clinical presentation (approximately three to thirty days after tick bite) may include fever, chills, headache, fatigue, myalgias/arthralgias, swollen lymph nodes, and erythema migrans (EM) skin lesions.

    If untreated, later manifestations (days to months after bite) can affect multiple organ systems and include additional EM lesions, facial palsy, Lyme arthritis with severe joint pain and swelling (often the knee), neurologic involvement (e.g., meningitis, radiculoneuritis, nerve pain), cardiac manifestations (palpitations, conduction abnormalities), and symptoms of central nervous system inflammation. The policy notes that when EM is present, clinical diagnosis and treatment should proceed without laboratory testing.

    Definitions and Notes

    EM (erythema migrans) — definition and clinical diagnosis guidance
    DefinitionErythema migrans (EM) — a painless 'bulls-eye' rash at the site of a tick bite.
    Clinical diagnosis guidanceWhen EM is present, individuals should be clinically diagnosed and treated for Lyme disease without the need for laboratory testing.
    ContextEM is listed in Note 1 as a sign of early untreated Lyme disease and is a primary clinical trigger for diagnosis rather than serologic testing.
    MTTT (Modified two-tiered testing) — description of algorithm replacing second-tier western blot with FDA-cleared EIA
    Algorithm descriptionMTTT (Modified two-tiered testing) replaces the traditional second-tier western blot with an FDA-cleared EIA (or other FDA-cleared assay) as the confirmatory test following a positive or equivocal first-tier EIA/IFA.
    Intended benefit
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyLyme Disease Testing
    Policy CodePolicy AHS - G2143 - Lyme Disease Testing
    Change TypeReorganization + material criteria additions
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateSep 15, 2026
    Key ActionWhen symptoms persist after a negative serologic test, repeat serologic testing meets coverage if performed no sooner than 4 weeks after the prior test.
    SourceLink
    On This Page
    Coverage Criteria for Lyme Disease TestingApplicable Procedure and Proprietary CodesProvider Requirements, Documentation, and Denial RisksBackground and Evidence SummaryDefinitions and Notes

    CDC/IDSA/AAP/NICE guidance advise against testing in these scenarios to avoid false positives and unnecessary treatment.

    Asymptomatic screening is not supported and former subcriteria for nonspecific symptom testing were removed and reallocated into reorganized criteria.

  1. Attach clinical notes showing the covered indication when submitting testing codes.
  2. Billing Rule

    Applicable procedure codes: list and operational guidance

    The following CPT/HCPCS and proprietary codes are listed as applicable procedure codes for Lyme disease testing; ensure coding on claims matches documentation and any off-cycle additions noted in the revision history.

    • Include codes such as 86617, 86618, 87475, 87476, 0041U, 0042U, 0316U and off-cycle additions 0580U and 0615U as appropriate on claims.
    • Match the selected procedure code to the specific test performed and the supporting clinical documentation.
    Step Therapy

    Preferred diagnostic algorithm: two-tier serologic testing

    Use a two-tier serologic testing approach: perform a sensitive EIA or IFA as the first step, and if positive or equivocal, proceed to a confirmatory western immunoblot or an FDA-cleared second EIA (modified two-tier testing).

    • If first-step EIA/IFA is negative, no further testing of that specimen is recommended.
    • When FDA-cleared second-tier EIA is used, it replaces the western immunoblot as the confirmatory test per CDC guidance.
    Step Therapy

    Recommended testing sequence: EIA/IFA then reflex confirmatory testing

    Follow a two-step testing sequence: first-tier EIA or IFA; if the result is positive or equivocal, reflex to an immunoblot (western blot) or an FDA-cleared second EIA per CDC/AAP/NICE recommendations.

    • If the first-tier EIA/IFA is negative, no further testing of the specimen is indicated.
    • Perform second-tier testing only when first-tier is positive or equivocal.
    Note
    Documentation Required

    Required clinical documentation: travel/exposure and signs/symptoms

    Document the individual's history of travel to a Lyme-endemic region when applicable, and record signs and symptoms consistent with early or later Lyme disease as defined in Note 1.

    • Include travel/exposure history (e.g., outdoor activities, contact with wildlife) when relevant.
    • Reference Note 1 for the list of early and later signs/symptoms to justify testing.
    Documentation Required

    Required clinical documentation: signs/symptoms, exposure, and timing

    Document specific clinical signs or syndromes (e.g., erythema migrans when applicable, neurologic syndromes, arthritis, myocarditis) and epidemiologic exposure, and record timing of specimen collection (acute vs convalescent) relative to symptom onset.

    • Specify the clinical presentation from the policy's covered list (e.g., meningitis, radiculoneuritis, Lyme arthritis).
    • Note timing of symptoms and specimen collection to support serologic interpretation.
    Documentation Required

    Repeat serologic testing documentation: persistent symptoms and interval

    When repeating serologic testing after a prior negative result, document persistent symptoms and ensure the repeat test is performed no sooner than four weeks after the previous serologic test.

    • Record clinical persistence of symptoms as the reason for repeat testing.
    • Verify that at least four weeks have passed since the prior serologic test before repeating.
    Denial Risk

    Triggers for denial: asymptomatic screening, EM, or lack of clinical support

    Claims for serologic testing may be denied when testing is ordered for asymptomatic individuals, for persons with erythema migrans (EM) where laboratory testing is not indicated, or when testing is performed without clinical or epidemiologic support as defined in the policy.

    • Testing asymptomatic individuals or routine screening is not covered.
    • EM lesions should be clinically diagnosed and treated without laboratory testing.
    Denial Risk

    Improper testing scenarios that risk denial

    Testing scenarios that risk denial include serologic testing of asymptomatic patients after a tick bite, ordering tests without clinical or epidemiologic support, and performing a western immunoblot without a prior EIA/IFA.

    • Do not order serology for asymptomatic individuals following a tick bite.
    • Avoid ordering western immunoblot as the initial test if no prior EIA/IFA was performed or if first-tier is negative.
    Denial Risk

    Asymptomatic screening and nonspecific symptoms: not supported

    Do not screen asymptomatic individuals (including those in endemic areas); testing for nonspecific or vague symptoms without meeting the policy's defined symptomatic criteria is not supported and may be denied.

    • Removed allowance for testing asymptomatic individuals living in endemic areas—screening is not supported.
    • Testing for nonspecific symptoms was removed and is not covered unless the presentation meets defined criteria.
    MTTT has been reported to improve sensitivity for early infections while maintaining comparable specificity to STTT.
    Regulatory contextFDA-cleared serologic assays (e.g., ZEUS ELISA) permit use of EIA as the second test in the two-tier algorithm when cleared for that purpose, per CDC guidance.
    STTT — Standard two-tier testing definition and context
    DefinitionSTTT (Standard two-tier testing) — initial screening with an EIA or IFA followed, if positive or equivocal, by a second-tier immunoblot (western blot) for confirmation.
    Interpretation ruleIf first-tier EIA/IFA is negative, no further testing is recommended; results are considered positive only if both first- and second-tier tests are positive.
    Guideline alignmentCDC, AAP and related guideline statements endorse the two-step process and note FDA-cleared alternatives may be acceptable when specified.
    MTTT (alternate inventory entry) — modified two-tier testing details and sensitivity rationale
    MTTT detailsModified two-tier testing substitutes a second EIA (FDA-cleared) for the immunoblot, aiming to reduce missed positive samples and improve laboratory efficiency.
    Sensitivity rationaleStudies report MTTT increases sensitivity for early Lyme disease compared with STTT and has equivalent sensitivity for late-stage infections, with comparable specificity.
    LimitationsMTTT may not capture infections caused by some non‑B. burgdorferi species; check validation for strains and regional differences.
    Molecular testing (PCR/WB‑RTPCR) — definition and clinical limitations/considerations
    DefinitionMolecular testing (e.g., PCR or WB‑RTPCR) — assays that detect Borrelia burgdorferi DNA in clinical specimens.
    Clinical limitationsMolecular tests have variable sensitivity depending on sample type; blood PCR is often negative and not routinely recommended, while joint fluid PCR may be informative for Lyme arthritis.
    Complementary roleMolecular testing can identify some early infections missed by serology and may be useful in suspected early Lyme disease or reinfection, but results require clinical correlation.
    LDT — laboratory-developed test definition
    DefinitionLDT (Laboratory-developed test) — a test developed and validated by an individual laboratory and regulated as a high-complexity test under CLIA; not FDA-approved or -cleared.
    Regulatory noteLDTs are performed in-house and must be validated by the performing laboratory; FDA clearance is not currently required for clinical use.
    ImplicationClinical performance and validation can vary by laboratory; review LDT validation when interpreting results.
    Note 1 (signs/symptoms) — Note defining signs/symptoms of early and late untreated Lyme disease referenced in criteria
    Note 1 purposeDefines signs and symptoms of early and late untreated Lyme disease used throughout the coverage criteria.
    Early disease examplesEarly signs/symptoms include erythema migrans (EM) and other typical early manifestations occurring approximately 3–30 days after exposure; EM should be clinically diagnosed without laboratory testing.
    Late disease examplesLate manifestations include neurologic syndromes, Lyme arthritis, and cardiac involvement (e.g., myocarditis/pericarditis) as described in the criteria.